Biotron Limited
0.00
AUD
0.00
(0.00%)
Biotron Limited
ASX:BIT
(Australian Securities Exchange)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Biotron Limited (ASX:BIT), a clinical-stage biotechnology company founded in 1999 and headquartered in Sydney, Australia, develops and commercializes small molecule antivirals targeting viroporin proteins essential to viruses including HIV-1, hepatitis C virus (HCV), hepatitis B virus (HBV), SARS-CoV-2, dengue, Zika, influenza and respiratory syncytial virus (RSV); its lead product BIT225 advances in Phase 2 trials for HIV-1 and HCV, demonstrating inhibition of HIV replication in macrophage reservoirs to potentially enable viral eradication when combined with antiretrovirals, alongside preclinical HBV candidate BIT-HBV001 showing robust antiviral activity in mouse models and in vitro assays, a proprietary bacterial screening platform supporting a library of over 350 compounds, and early research into SARS-CoV-2 treatments. The company operates primarily in Australia with a global development focus targeting unmet needs in viral infectious diseases for patients and healthcare providers worldwide. In 2025, Biotron announces the acquisition of Sedarex Limited for AU$1.5 million in shares plus milestones, adding SedRx, a patented next-generation general anesthetic with FDA/EMA pathways offering improved safety over prior formulations like Althesin; the deal, subject to shareholder approval and expected completion by December 2025, includes a AU$2.5 million capital raising via placement and rights issue to fund SedRx regulatory advancement, neurological indications and ongoing antiviral programs, diversifying into anesthesia and neuroscience.